Právní předpis byl sestaven k datu 25.12.2012.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x doplňuje xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. s., x. 46/2008 Xx. x. x. x x. 47/2012 Sb. m. x. x Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Nové xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s xxxxxxx 34 odst. 3 Xxxxxx dne 1. xxxxx 2012 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu platné xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx překlad xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx
Paříž, 1. xxxxx 2012
SEZNAM XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Xxxxx xxxxxx 4.2.2 Světového antidopingového xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx ze xxxxxx X1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, M2 x X3.
XXXXX X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX) |
XXXXXXXX LÁTKY
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není aktuálně xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. léčiva x preklinickém nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, pokud xxxx podány exogenně:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxx metabolity x isomery, xxx xx x xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx na ně.
Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" se xxxxxxxx x xxxxx, xxxxxx xxxx není xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, kterou může xxxx produkovat přirozeně. |
X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ FAKTORY X PŘÍBUZNÉ LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx uvolňující xxxxxxx xxxx xxxxxxxx:
1. Xxxxx stimulující erytropoesu (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), methoxypolyethylenglykol-epoetin xxxx (XXXX), peginesatid /Hematide/);
2. Choriogonadotropin (CG) x Xxxxxxxxxxxx xxxxxx (XX) u xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx růstový faktor (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), stejně xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx zakázáni xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 mikrogramů xx 24 xxxxx) x salmeterolu xxxxx xxxx xxxxxx v xxxxxxxx x xxxxxxx x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 30 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx považována xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.
S4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
Zakázané je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, ale xx x omezením xxxxx xx ně.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x součinnosti s XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) xxxx agonists/ (např. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a mannitolu), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Diuretika zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě drospirenonu, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro použití (Xxx Soutěži, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení specifické Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx navíc x xx, xxxxx xxx byla xxxxxxx xx diuretikum nebo xxxxx xxxxxxxxx látku.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX KYSLÍKU
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx doping, xxxxxx použití xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované hemoglobinové xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie x efaproxiral (RSR13), xxx ne s xxxxxxxx xxxxx xx xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za účelem xxxxxxx xxxxxxxxx a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx kontrole xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. proteázami) xxxx, xxx xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx než 50 ml za 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx a xxxxxxxxx jakéhokoliv množství xxxx krve xx xxxxxxxxx systému xx xxxxxxxx.
X3. GENOVÝ XXXXXX
X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx sekvencí;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX SOUTĚŽI |
Xxxxx xxxxxxxxx XX xx X5 x X1 až X3 xxxxxxxxx xxxx jsou Xxx Soutěži xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx, s xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, benzylpiperazin, xxxxxxxxx, dimethylamfetamin, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), furfenorex, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, prenylamin, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx stimulancia (příklady):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, fenprometamin, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 2012 (bupropion, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx látky.
** Xxxxxxx xxxxxx adrenalinu (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 ml xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (např. xxxxx, xxxxxx a marihuana) xxxx syntetický xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ a XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
LÁTKY XXXXXXXX V URČITÝCH XXXXXXXX |
P1. XXXXXXX
Xxxxxxx (xxxxxx) xx zakázaný pouze Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Detekce xx bude xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx krve. Prahová xxxxxxx pro porušeni xxxxxxxxxxx pravidla (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (FIM)
∙ Xxxxx motorismus (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou zakázány xxxxx Při Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Automobilový xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxxx (FMB)
∙ Xxxx (IGF)
∙ Kuželky x xxxxxxx (FIQ)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard U-rampa x "xxx xxx"
∙ Xxxxxxxx x xxxxxxx sporty (CMSB)
∙ Střelba (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx zahrnují následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx předpisem č. 98/2013 Sb. m. s. x xxxxxxxxx od 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.